Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia

•58,637 doses of 4CMenB vaccine were administered to 30,522 students.•193 AEFI including nine serious adverse events in 187 students were reported.•The AEFI reporting rate was low and consistent with other adolescent vaccines. Four-component meningococcal B (4CMenB) vaccine is licensed in many count...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2020-08, Vol.38 (37), p.5914-5922
Hauptverfasser:	Marshall, H.S., Koehler, A.P., Wang, B., A'Houre, M., Gold, M., Quinn, H., Crawford, N., Pratt, N., Sullivan, T.R., Macartney, K.
Format:	Artikel
Sprache:	eng
Schlagworte:	4CMenB Adolescent Adolescents Adverse events Age Australia - epidemiology Committees Control methods Ethics Female Headache Headaches Humans Immunization Infant Meningococcal B disease Meningococcal disease Meningococcal Infections - epidemiology Meningococcal Infections - prevention & control Meningococcal Vaccines - adverse effects Nausea Odds Ratio Pregnancy Randomization Safety Schools South Australia - epidemiology Students Surveillance Teenagers Vaccine safety Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!